At its Committee Summit in London today, the UK Bioindustry Association (BIA) launched its new Genomics Advisory Committee to support the strategic objective that "the UK starts, scales, and builds world leading genomic businesses".
Companies and organizations represented on the Committee include Congenica, Eagle Genomics, Genomics plc, Global Gene Corp, LGC Ltd, NewGene ltd, Oxford Nanopore Technologies Ltd, and the Wellcome Sanger Institute.
The Committee will act as a leadership platform for sharing and discussing issues of common concern between genomic businesses and will provide expert advice on important issues such as the use of data and embedding genomic medicine in the NHS. It has already got off to a flying start through supporting a panel on genomics that the BIA participated with alongside partners in San Francisco in January during the 36th annual JP Morgan Healthcare Conference.
BIA Chief Executive, Steve Bates commented: “Genomic medicine is on the brink of transforming healthcare and the UK is at the forefront of this revolution. Convening this group will strengthen the voice of UK industry at an exciting and interesting time for genomics, working to ensure that the UK environment remains supportive and internationally competitive for genomic SMEs.”
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.